F. Li and J. Fraumeni, Soft-Tissue Sarcomas, Breast Cancer, and Other Neoplasms, Annals of Internal Medicine, vol.71, issue.4, pp.747-52, 1969.
DOI : 10.7326/0003-4819-71-4-747

D. Malkin, F. Li, L. Strong, J. Fraumeni, C. Nelson et al., Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms, Science, vol.250, issue.4985, pp.1233-1241, 1990.
DOI : 10.1126/science.1978757

F. Toledo and G. Wahl, Regulating the p53 pathway: in vitro hypotheses

D. Malkin and . Li-fraumeni-syndrome, Li-Fraumeni Syndrome, Genes & Cancer, vol.2, issue.4, pp.475-84, 2011.
DOI : 10.1177/1947601911413466

URL : https://hal.archives-ouvertes.fr/hal-01262929

A. Petitjean, E. Mathe, S. Kato, C. Ishioka, S. Tavtigian et al., mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database, Human Mutation, vol.47, issue.6, pp.622-631, 2007.
DOI : 10.1002/humu.20495

A. Mukeria, L. Calvez, F. Hung, R. , R. H. Cortot et al., Network Genomic Medicine (NGM) A genomics-based classification of human lung tumors Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history, Clinical Lung Cancer Genome Project (CLCGP) Sci Transl Med Cancer Res, vol.567, pp.5667-72, 2007.

M. Ronco and L. Pujantell-pastor, Nondisruptive p53 mutations are associated with shorter survival in advanced non-small-cell lung cancer patients, Clin Cancer Res Off J Am Assoc Cancer Res, 2014.

J. Xu, J. Qian, Y. Hu, J. Wang, X. Zhou et al., Heterogeneity of Li-Fraumeni syndrome links to unequal gain-of-function effects of p53 mutations. Sci Rep, Feb, vol.274, p.4223, 2014.

V. Serra, A. Vivancos, X. Puente, E. Felip, D. Silberschmidt et al., Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel HER2V659E Mutation, Cancer Discovery, vol.3, issue.11, pp.1238-1282, 2013.
DOI : 10.1158/2159-8290.CD-13-0132

Y. Jia, S. Ali, S. Saad, C. Chan, V. Miller et al., Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB extracellular domain S310F mutations with the pan- HER inhibitor afatinib, Cancer Biol Ther, vol.15, 2014.